# Pragmatica-Lung (NCT05633602)

> Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05633602
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: SWOG Cancer Research Network
- Conditions: Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8
- Interventions: Chemotherapy; Pembrolizumab; Ramucirumab
- Enrollment: 838
- Primary outcome: Overall survival

## Indexed commentary on Pragmatica-Lung so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 15
- YouTube: 8
- Podcasts: 7

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=pragmatica-lung-nct05633602

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05633602", "email": "<work email>"}; the inbox owner confirms by the emailed link.